|1.||Wu, Hua-Lin: 14 articles (11/2015 - 01/2002)|
|2.||Shi, Guey-Yueh: 13 articles (11/2015 - 01/2002)|
|3.||Conway, Edward M: 10 articles (12/2015 - 05/2004)|
|4.||Li, Yi-Heng: 10 articles (11/2015 - 01/2002)|
|5.||Ostrowski, Sisse R: 10 articles (02/2015 - 01/2011)|
|6.||Johansson, Pär I: 10 articles (02/2015 - 01/2011)|
|7.||Maruyama, Ikuro: 9 articles (01/2013 - 09/2004)|
|8.||Esmon, Charles T: 8 articles (07/2015 - 01/2003)|
|9.||Ikezoe, Takayuki: 8 articles (01/2015 - 11/2010)|
|10.||Mysliwiec, M: 8 articles (01/2009 - 10/2002)|
04/01/2014 - "The coadministration of AT and recombinant thrombomodulin is effective for the suppression of leukocyte activation and cell death during sepsis."
01/01/2015 - "The safety and efficacy of recombinant human soluble thrombomodulin (rhTM) have been demonstrated, with promising evidence suggestive of efficacy for patients with severe sepsis involving coagulopathy in a phase IIb randomized controlled trial. "
03/01/2013 - "Several preclinical studies in experimental sepsis models have shown that administration of soluble thrombomodulin is capable of improving the derangement of coagulation, ameliorates inflammatory responses and may restore organ dysfunction. "
04/01/2003 - "Soluble thrombomodulin has been shown to improve ALI in animals, and it is currently being evaluated in humans with sepsis. "
03/01/2014 - "This study reveals for the first time a detrimental role for the thrombomodulin lectin-like domain in the host response to sepsis caused by a clinically relevant Gram-negative pathogen."
|2.||Disseminated Intravascular Coagulation
01/01/2015 - "The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study."
02/01/2015 - "Observational study to compare antithrombin and thrombomodulin for disseminated intravascular coagulation."
04/01/2011 - "Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial."
08/01/2015 - "Recombinant soluble thrombomodulin for postoperative disseminated intravascular coagulation."
01/01/2015 - "Recombinant human soluble thrombomodulin (rhTM) is a new drug for the treatment of disseminated intravascular coagulation in Japan. "
|3.||Septic Shock (Toxic Shock Syndrome)
05/01/1998 - "Septic shock nonsurvivors had significantly greater mean thrombomodulin concentrations (10.6 +/- 2.2 ng/mL) than septic shock survivors (5.5 +/- 0.6 ng/mL) (p < .05) and healthy control patients (3.4 +/- 0.2 ng/mL) (p < .01). "
01/01/1998 - "These data suggest that plasma thrombomodulin and vWF may be related to septic shock and that PMX-F is effective in reducing these factors in patients with septic shock."
05/01/1998 - "We speculate that measurement of plasma thrombomodulin concentrations in septic shock may be a useful indicator of the severity of endothelial damage and the development of multiple organ system failure."
05/01/1998 - "Pediatric survivors and nonsurvivors of septic shock have circulating thrombomodulin concentrations 1.5 and 3 times greater than healthy control patients. "
05/01/1998 - "Blood samples were obtained for plasma thrombomodulin determinations every 6 hrs for 72 hrs in septic shock patients and once in healthy control patients. "
04/01/2006 - "The role of thrombomodulin in atherosclerosis: from bench to bedside."
01/01/2006 - "Thrombomodulin (TM) has been described as a marker of endothelial injury in atherosclerosis. "
01/01/2004 - "Soluble thrombomodulin in patients with established atherosclerosis."
06/01/2003 - "These results suggest that circulating levels of thrombomodulin are elevated in hypertensive patients as compared to normotensive subjects and that the thrombomodulin level may be a molecular marker of the latent progression of atherosclerosis in hypertensive patients."
06/01/2003 - "Circulating thrombomodulin levels are related to latent progression of atherosclerosis in hypertensive patients."
|5.||Vascular System Injuries
11/01/2006 - "Mean s-thrombomodulin concentrations, a marker for endothelial cell injury, were highest in rabbits exposed to US at 0.85 and 3.9 MPa, suggesting that vascular injury may be physiological and not accompanied by irreversible cellular injury."
10/01/1998 - "The normal values obtained in FH children for plasma thrombomodulin suggest that the hemorheological alterations appear prior to the vascular injury, are in part related to dyslipemia and could contribute to the development of the atherosclerotic process by modifying blood flow conditions."
11/01/1997 - "The upregulation of thrombomodulin (CD141) is noteworthy since it is a marker of EC damage and thus may be a useful reagent in investigations of vascular injury. "
02/01/1997 - "Effect of human urinary thrombomodulin on endotoxin-induced intravascular coagulation and pulmonary vascular injury in rats."
09/01/1996 - "We therefore examined whether recombinant human soluble thrombomodulin (rhs-TM) prevents activated leukocyte-induced pulmonary vascular injury in rats receiving ET. "
|2.||Plasminogen Activators (Plasminogen Activator)
|3.||Thromboplastin (Tissue Factor)
|4.||Tissue Plasminogen Activator (Alteplase)
|6.||Fibrinogen (Factor I)
|7.||Plasminogen Activator Inhibitor 1
|9.||Factor VII (Proconvertin)
|10.||von Willebrand Factor
|2.||Platelet Transfusion (Blood Platelet Transfusions)